$0.08
+54.37%Price chart
Jul 15Jul 29Aug 5Aug 19Sep 11Sep 21Oct 5Oct 19
Key dataOct 19, 2026
Open$0.08
From 52W high−65.55%
Volume500.00
Market cap$3.01M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$0.08
From 52W high
−65.55%
Volume
500.00
Market cap
$3.01M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.3x
P/E (TTM)
—
RSI (14)
51.0
MomentumView details →
1D Return
+54.37%
YTD Return
+62.40%
SummaryUpdated Jun 1, 2026
Estrella Immunopharma, Inc. (NASDAQ:ESLA) is a preclinical-stage biopharmaceutical company founded to develop innovative T-cell therapies for treating blood cancers and solid tumors. Based in Emeryville, California, the company went public in September 2021 and focuses on developing engineered T-cell immunotherapies designed to harness the body's immune system to fight cancer. As a preclinical company, Estrella has not yet generated revenue and remains in the research and development phase of bringing its therapeutic candidates through clinical trials toward potential commercialization.
Similar companies
Latest newsMore news →
Estrella Immunopharma, Inc. announced that the first patient in the STARLIGHT-1 dose-expansion phase tolerated two EB103 infusions of 5 × 10⁶ T cells/kg, given three weeks apart, well during the first month, with no treatment-related serious adverse events reported.5d agoEstrella Immunopharma, Inc. announced that Intermountain Health Platte Valley Hospital LDS Hospital has been activated as the fifth clinical site for its ongoing STARLIGHT-1 Phase I/II trial of EB103 in patients with relapsed B-cell non-Hodgkin's lymphoma.6d agoEstrella Immunopharma activated University Hospitals Cleveland Medical Center as the fourth clinical site for its Phase I/II STARLIGHT-1 trial of EB103 in B-cell non-Hodgkin's lymphoma.70d ago